NCT05472337RecruitingPhase 2
Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 31 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This randomized clinical trial will determine the treatment effect of colchicine (1.5 mg loading dose and 0.5 mg daily thereafter) for 6 weeks on microvascular coronary reperfusion and infarct size in patients with acute coronary syndrome.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 23 May 2022
- Start date
- 1 Aug 2022
- Primary completion date
- 30 Mar 2026
- Lead sponsor
- Pontificia Universidad Catolica de Chile
- Diseases
- Coronary artery disease
- NCT number
- NCT05472337
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 1 Aug 2022 to the primary completion date, 30 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Related to colchicine use: known intolerance, previous use for another condition (e.g., gout), severe liver disease (e.g., severe liver disease).
Other illness
- ST-segment elevation myocardial infarction (undergoing emergency angioplasty therefore not allowing time for the administration and effect of colchicine).
- Any other disease that limits life expectancy to \<1 year.
- Medical history of a disorder that could, in the opinion of the treating physician, place the participant at significant risk if they were to participate in the trial.
Lab values
- Advanced heart failure, left ventricular ejection fraction \<35%.
- Severe liver disease (transaminase elevation 3 times above normal), blood dyscrasia (leukocyte or platelet count lower than normal), glomerular filtration rate (MDRD), use of CYP3A4 or calcineurin inhibitors, active autoimmune disease or the use of chronic anti-inflammatory therapy, concomitant infection, pregnancy or concomitant infection, pregnancy or lactation.
Other
- Severe left main stenosis.
Who the study is looking for
- Age ≥18 years.
- Adults hospitalized at the Clinical Hospital of the Catholic University for an ACS condition, defined as:
- \- Presence of chest pain, associated with enzymatic elevation (increase of ultrasensitive troponin above normal value (99th percentile)) with or without electrocardiographic changes.
- Patients undergoing coronary angiography with the intention of angioplasty in the next few days (during the index hospitalization).
- Ability and willingness to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clínico Pontificia Universidad Católica de Chile Coordinator of this site? Confirm its status | Santiago | Chile | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.